For prescribing information and adverse event reporting, click here

This section of the website is for UK Healthcare Professionals only. 
If you are not a Healthcare Professional, please click here.

This website has been commissioned by Ipsen UK and is intended for a UK audience.

IQIRVO®▼ (elafibranor) therapeutic indication1

IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.1

IQIRVO

IQIRVO

Mechanism of action

IQIRVO provides a multi-targeted approach

While the exact mechanism by which IQIRVO exerts its therapeutic effects in patients with PBC is not fully understood, it is thought that PPAR-α and PPAR-δ are key regulators of bile acid homeostasis, inflammation and fibrosis.

IQIRVO provides a multi-targeted approach

Abbreviations

PBC, primary biliary cholangitis; PPAR α/δ, peroxisome proliferator-activated receptor alpha + delta

Reference

  1. IQIRVO® (elafibranor) Summary of product characteristics (SmPC). 2024.
Resources

Contact your Ipsen representative

Send request

To access relevant information about Primary Biliary Cholangitis, please confirm the following:

I am a UK Healthcare Professional

This section is for UK healthcare professionals only. Contains promotional information

I am a UK Healthcare Professional

I am a patient

This section provides information to support patients that have been prescribed IQIRVO®▼ (elafibranor).

I am a patient

I am a member of the general public

This section is for members of the general public.

I am a member of the general public

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in Google Play or Apple App Store. Side effects should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone 01753 627777. By reporting side effects, you can help provide more information on the safety of this medicine.